Adenocarcinoma of the penis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:398053C60.1C60.2C60.8
Who is this for?
Show terms as
1FDA treatments7Active trials20Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Adenocarcinoma of the penis is an extremely rare type of cancer that develops in the glandular cells of the penis. Unlike the more common squamous cell carcinoma of the penis, adenocarcinoma arises from mucus-producing glands or other glandular tissue in the penile skin, urethra, or accessory glands (such as Cowper's glands, Littre's glands, or sweat glands). Because it is so uncommon, it is often diagnosed at a later stage when symptoms become more noticeable. Symptoms may include a lump or mass on the penis, unusual discharge from the urethra, bleeding, pain, or changes in the skin of the penis. Some patients notice swelling in the groin area due to enlarged lymph nodes. The disease can spread to nearby lymph nodes and, in advanced cases, to distant organs. Treatment depends on the stage and location of the tumor. Options may include surgery (ranging from local excision to partial or total penectomy), radiation therapy, and chemotherapy. Because this cancer is so rare, treatment plans are often individualized and may be guided by approaches used for other penile cancers or adenocarcinomas at other body sites. Early detection and treatment offer the best chance for a favorable outcome. Patients are typically managed by a multidisciplinary team including urologists, oncologists, and surgeons with experience in rare cancers.

Also known as:

Key symptoms:

A lump or growth on the penisUnusual discharge from the tip of the penisBleeding from the penisPain in the penisChanges in the color or texture of penile skinThickening of the skin on the penisSwollen lymph nodes in the groinDifficulty urinating or changes in urine streamA sore or ulcer on the penis that does not healFoul-smelling dischargeUnexplained weight loss in advanced casesFatigue in advanced cases

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

9 events
Aug 2025E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Christian Hinrichs — PHASE1, PHASE2

TrialRECRUITING
Aug 2025Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center — PHASE1

TrialRECRUITING
Nov 2024Ivonescimab in the Treatment of Multiple Advanced Tumors

Fudan University — PHASE2

TrialRECRUITING
Mar 2023E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs — PHASE2

TrialRECRUITING
Oct 2022A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

National Cancer Institute (NCI)

TrialRECRUITING
Sep 2019Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

University of Utah — PHASE2

TrialACTIVE NOT RECRUITING
May 2019Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING
Dec 2017Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute — PHASE2

TrialACTIVE NOT RECRUITING
Jul 2015Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI) — PHASE1

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Abraxane

paclitaxel protein-bound particles· Abraxis BioScience, LLC■ Boxed Warning

ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

Clinical Trials

7 recruitingView all trials with filters →
Phase 24 trials
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Phase 2
Active
PI: Bradley A McGregor, MD (Dana-Farber Cancer Institute) · Sites: La Jolla, California; Atlanta, Georgia +4 more · Age: 1899 yrs
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Phase 2
Actively Recruiting
PI: Christian S Hinrichs, MD (Rutgers Cancer Institute) · Sites: Bethesda, Maryland; New Brunswick, New Jersey +1 more · Age: 1899 yrs
Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2
Actively Recruiting
PI: Hongxia Wang, Doctor (Fudan University) · Sites: Shanghai, Shanghai Municipality · Age: 1899 yrs
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2
Actively Recruiting
PI: Andrea B Apolo (Alliance for Clinical Trials in Oncology) · Sites: Birmingham, Alabama; Anchorage, Alaska +578 more · Age: 1899 yrs
Phase 12 trials
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Phase 1
Active
PI: Andrea B Apolo (National Cancer Institute LAO) · Sites: Duarte, California; Los Angeles, California +6 more · Age: 1899 yrs
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1
Actively Recruiting
PI: Jeremie Calais (UCLA / Jonsson Comprehensive Cancer Center) · Sites: Los Angeles, California · Age: 1899 yrs

Specialists

20 foundView all specialists →
AA
Andrea B Apolo
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 4 active trials
HD
Hongxia Wang, Doctor
Specialist
PI on 2 active trials
CD
Camila MV Moniz, Doctor
SAN ANTONIO, TX
Specialist
PI on 1 active trial
DM
Dawn Pinchasik, MD
PITTSBURGH, PA
Specialist
PI on 2 active trials
SM
Shivaani Kummar, MD
PORTLAND, OR
Specialist
PI on 5 active trials
MP
Marie A Bakitas, PhD
LEBANON, NH
Specialist
PI on 1 active trial
BM
Balaji Reddy, MD
BOSTON, MA
Specialist
PI on 1 active trial
AS
Alejandro Sanchez
Salt Lake City, Utah
Specialist

Rare Disease Specialist

PI on 2 active trials53 Adenocarcinoma of the penis publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Adenocarcinoma of the penis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Adenocarcinoma of the penisForum →

No community posts yet. Be the first to share your experience with Adenocarcinoma of the penis.

Start the conversation →

Latest news about Adenocarcinoma of the penis

Disease timeline:

New recruiting trial: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: Ivonescimab in the Treatment of Multiple Advanced Tumors

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New recruiting trial: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A new clinical trial is recruiting patients for Adenocarcinoma of the penis

New trial: Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

Phase PHASE2 trial recruiting. Hypofractionated Radiation Therapy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific type and stage of penile cancer do I have, and what does that mean for my treatment options?,What are the benefits and risks of each treatment option, including surgery, radiation, and chemotherapy?,How will treatment affect my urinary and sexual function?,Are there any clinical trials available for this type of cancer?,What follow-up care and monitoring will I need after treatment?,Can you refer me to a specialist or cancer center with experience treating rare penile cancers?,What psychological or emotional support services are available to me and my family?

Common questions about Adenocarcinoma of the penis

What is Adenocarcinoma of the penis?

Adenocarcinoma of the penis is an extremely rare type of cancer that develops in the glandular cells of the penis. Unlike the more common squamous cell carcinoma of the penis, adenocarcinoma arises from mucus-producing glands or other glandular tissue in the penile skin, urethra, or accessory glands (such as Cowper's glands, Littre's glands, or sweat glands). Because it is so uncommon, it is often diagnosed at a later stage when symptoms become more noticeable. Symptoms may include a lump or mass on the penis, unusual discharge from the urethra, bleeding, pain, or changes in the skin of the p

How is Adenocarcinoma of the penis inherited?

Adenocarcinoma of the penis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Adenocarcinoma of the penis typically begin?

Typical onset of Adenocarcinoma of the penis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Adenocarcinoma of the penis?

Yes — 7 recruiting clinical trials are currently listed for Adenocarcinoma of the penis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Adenocarcinoma of the penis?

20 specialists and care centers treating Adenocarcinoma of the penis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.